- Completed Enrollment in Phase 1 Dose Escalation with Oral Fadraciclib in Solid Tumors -
- No Dose Limiting Toxicities Observed at All Dose Levels Enrolled to Date -
- Demonstrated Evidence of Target Engagement for CDK2 and CDK9 -
- Early Anticancer Activity, Including Partial Response and Stable Disease with Tumor Shrinkage,Observed in Patients with Endometrial Cancer, Pancreatic Cancer and T Cell Lymphoma -
- R&D Day Planned for Fall 2022 -
BERKELEY HEIGHTS, N.J., June 30, 2022... More